UPDATE: Ladenburg Thalmann Starts BiomX (PHGE) at Buy

April 15, 2021 6:39 AM EDT
Get Alerts PHGE Hot Sheet
Price: $3.17 --0%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 3 | New: 9
Trade Now! 
Join SI Premium – FREE
(Updated - April 15, 2021 6:57 AM EDT)

Ladenburg Thalmann analyst Mike Higgins initiates coverage on BiomX (NYSE: PHGE) with a Buy rating and a price target of $25.00.

The analyst comments "We are initiating coverage of BiomX Inc. (PHGE) with a Buy rating and $25 price target. BiomX is a biotechnology company that is internally developing clinical-stage phages as a novel approach in six different medical conditions. BiomX is an Israeli-based, six-year-old company that went public in November 2017 via a merger with a SPAC. In our view, there is an increased investor interest for clinical-stage assets we call, “The Naturals”, including phage therapies, widely regarded as “…the most abundant organism on earth” (1031 particles)."

For an analyst ratings summary and ratings history on BiomX click here. For more ratings news on BiomX click here.

Shares of BiomX closed at $6.38 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Ladenburg Thalmann Financial Services, Definitive Agreement, SPAC